Accessibility: Skip TopNav
Figure 2: Waterfall Plot for Patients in the 200 mg Dose Cohort of the CPI-818 Phase 1/1b Clinical Trial for T Cell Lymphoma.
The plot shows the best percent change in tumor volume in the evaluable patients from the same group shown in Figure 1.
Format
JPEG
Quelle:
Corvus Pharmaceuticals, Inc.
Downloads
Originalgröße
Groß
Mittel
Klein